文献速递消化道肿瘤放疗

直肠癌放化疗后病理反应预测:晚期奥沙利铂给药的影响

Predicting pathological response after radio-chemotherapy for rectal cancer: Impact of late oxaliplatin administration.
PubMed 文献 · Radiother Oncol · 2020-05-15

结果显示,晚期省略OXA显著降低病理反应,且ERITCP评估后给予OXA显著影响ERITCP与pCR的关系。

要点

  • 晚期省略奥沙利铂显著降低pCR率(31.5% vs 14.3%)。
  • ERITCP对所有终点显示高阴性预测值(85-91%)。
  • pCR预测模型含ERITCP(OR: 0.93)和OXA周期(OR: 3.5),AUC=0.78。

核心结论

  • 晚期省略奥沙利铂显著降低病理反应。
  • ERITCP评估后给予奥沙利铂显著影响ERITCP与pCR的关系。

研究设计与样本

  • 奥沙利铂于第-14、0(放疗开始)和+14天给药,36例根据肿瘤医生偏好未接受最后周期。
  • 利用计划时和放疗中MRI计算ERITCP,在第三周期奥沙利铂给药前评估。
  • 采用多变量逻辑回归评估预测模型,并通过bootstrap内部验证。

主要发现

  • 两组(3 vs 2周期OXA)可评估术后数据分别为54/59和35/36例。
  • pCR率分别为31.5%和14.3%(p=0.01-0.07),pCR+cCR_ww率分别为33.9%和14.3%,RVC>10%率分别为27.8%和54.3%。
  • ERITCP对所有终点显示高阴性预测值(85-91%)。
  • pCR的逻辑预测模型包含ERITCP(OR: 0.93)和OXA周期(OR: 3.5),AUC=0.78。
  • bootstrap内部验证确认结果稳健性。

关键数值与推荐

  • pCR/pCR+cCR_ww/RVC>10%率:3周期OXA组为31.5/33.9/27.8%,2周期组为14.3/14.3/54.3%(p=0.01-0.07)。
  • ERITCP阴性预测值:85-91%。
  • pCR预测模型:ERITCP OR=0.93,OXA周期 OR=3.5,AUC=0.78。

临床怎么用

  • ERITCP可用于预测直肠癌新辅助放化疗后病理反应,高阴性预测值有助于识别可能避免手术的患者。
  • 晚期奥沙利铂给药周期数应纳入pCR预测模型,省略最后周期可能显著降低病理缓解。

局限性

  • 奥沙利铂最后周期省略基于肿瘤医生偏好,非随机分组。
  • 需外部验证确认ERITCP和OXA周期模型的普遍适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: A previously introduced index based on early tumor (GTV) regression (ERITCP) during neo-adjuvant radio-chemotherapy of rectal cancer was used to investigate the impact of changes of oxaliplatin (OXA) delivery on the prediction of pathological complete response (pCR) and residual vital cell (RVC) fraction. MATERIALS AND METHODS: Ninety-five patients were treated following an adaptive protocol (41.4 Gy/18fr; 2.3 Gy/fr) delivering a simultaneous integrated boost to the residual GTV in the last 6 fractions (3 Gy/fr). OXA was delivered on days -14, 0 (start of RT) and +14. Based on the oncologist's preference, the last OXA cycle was not administered for 36 patients. MRIs taken at planning and at mid-RT were used to calculate ERITCP, before the timing of the third OXA cycle. The impact of OXA cycles and the discriminative power of ERITCP in predicting the pathological response (pCR, RVC >10%) were quantified. Multivariate logistic regression was performed to assess predictive models. RESULTS: Two patients with complete clinical remission refused surgery (cCR_ww). Complete post-surgical data of 54/59 and 35/36 patients were available for the two groups (3 vs 2 OXA cycles). pCR/pCR + cCR_ww/RVC >10% rates were 31.5/33.9/27.8% and 14.3/14.3/54.3% respectively (p = 0.01-0.07). ERITCP showed high negative predictive value (85-91%) for all end-points. The logistic predictive model for pCR included ERITCP (OR: 0.93) and OXA cycles (OR: 3.5), with AUC = 0.78. Internal validation through bootstrap confirmed the robustness of the results. CONCLUSIONS: Late omission of OXA dramatically reduced the pathological response. OXA delivery after the assessment of ERITCP significantly influenced the relationship between ERITCP and pCR.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Broggi S, Passoni P, Gumina C, et al. Predicting pathological response after radio-chemotherapy for rectal cancer: Impact of late oxaliplatin administration. Radiother Oncol. 2020. PMID: 32417346. doi:10.1016/j.radonc.2020.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。